An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1423-0410|109|3|248-256

ISSN： 0042-9007

Source： VOX SANGUINIS, Vol.109, Iss.3, 2015-10, pp. : 248-256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end‐stage renal disease

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 32, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Administering intravenous immunoglobulin during infection is associated with infusion reactions in selected patients

By Khan S.  

Irish Journal of Medical Science, Vol. 180, Iss. 1, 2011-03 ,pp. : 125-128

Springer Publishing Company

Access to resources Recommend Favorite

Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG)

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 182, Iss. 1, 2015-10 ,pp. : 51-56

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population Pharmacokinetics of Intravenous Busulfan in Japanese Pediatric Patients With Primary Immunodeficiency Diseases

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 327-331

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Prospective, Randomized Trial of Intrathecal Injection vs. Epidural Infusion in the Selection of Patients for Continuous Intrathecal Opioid Therapy

By  

NEUROMODULATION: TECHNOLOGY AT THE NEURAL INTERFACE, Vol. 6, Iss. 3, 2003-07 ,pp. : 142-152

John Wiley & Sons Inc

Access to resources Recommend Favorite